8-K filing — CUMBERLAND PHARMACEUTICALS INC (CPIX)
Filed: 2026-08-04 AccNo: 0001087294-26-000058 Size: 437 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Cumberland Q2 Adj. EPS $(0.20) Down From $(0.13) YoY, Sales $166.458K Down From $380.797K YoY
Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.20) per share. This is a 53.85 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $166.458 thousand in sales
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 9:18 PM
- Checked
- Aug 4, 2026, 9:18 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cumberland Pharmaceuticals Declares $1.50/Share Special Dividend
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special
Read original at benzingaCumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data
Cumberland Pharma shares rose after Phase 2 data showed ifetroban improved heart function in Duchenne muscular dystrophy patients.
Read original at benzinga